Dr. Erin R. Alesi, MD | Richmond, VA ...

Dr. Erin R. Alesi

Claim this profile

Virginia Commonwealth University/Massey Cancer Center

Studies Squamous Cell Carcinoma
Studies Lung Cancer
14 reported clinical trials
20 drugs studied

Area of expertise

1Squamous Cell Carcinoma
Erin R. Alesi has run 7 trials for Squamous Cell Carcinoma. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Lung Cancer
Erin R. Alesi has run 7 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR negative

Affiliated Hospitals

Image of trial facility.
Virginia Commonwealth University/Massey Cancer Center
Image of trial facility.
VCU Massey Cancer Center At Stony Point

Clinical Trials Erin R. Alesi is currently running

Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Image of trial facility.

Cetuximab + Pembrolizumab

for Head and Neck Cancer

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting2 awards Phase 316 criteria

More about Erin R. Alesi

Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Erin R. Alesi has experience with
  • Pembrolizumab
  • Cisplatin
  • Carboplatin
  • Nivolumab
  • Intensity-Modulated Radiation Therapy
  • Pemetrexed

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Erin R. Alesi specialize in?
Is Erin R. Alesi currently recruiting for clinical trials?
Are there any treatments that Erin R. Alesi has studied deeply?
What is the best way to schedule an appointment with Erin R. Alesi?
What is the office address of Erin R. Alesi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security